We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Novacyt S.a. | LSE:NCYT | London | Ordinary Share | FR0010397232 | EUR1/15TH (CDI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.60 | 2.48% | 66.00 | 65.00 | 68.80 | 66.00 | 63.00 | 63.00 | 78,622 | 08:58:06 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| In Vitro,in Vivo Diagnostics | 22.49M | -25.73M | - | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMNCYT
RNS Number : 1866N
Novacyt S.A.
18 May 2020
Novacyt S.A.
("Novacyt" or the "Company")
Director/PDMR Shareholdings
Paris, France and Camberley, UK - 18 May 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 15 May 2020, the following Directors purchased ordinary shares of EUR1/15 each in the Company (the "Ordinary Shares"):
Hot Features
Premium
Director Title Number of Price paid Resultant % of issued
Ordinary per Ordinary beneficial share capital
Shares purchased Share holding
Chief Executive
Graham Mullis Officer 9,493 310 p 61,631 0.09%
----------------- ------------------ -------------- ------------ ---------------
Non-Executive
Director
James Wakefield & Chairman 20,000 304.9p 36,839 0.05%
----------------- ------------------ -------------- ------------ ---------------
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name
Graham Mullis, Chief Executive
Officer
-------------------------------- ---------------------------------
2. Reason for the Notification
-------------------------------------------------------------------
a) Position/status See 1(a) - classified as
a PDMR of the Company
-------------------------------- ---------------------------------
b) Initial notification/ Amendment Initial Notification
-------------------------------- ---------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Novacyt S.A.
-------------------------------- ---------------------------------
b) LEI 213800BWAC2BF295EG28
-------------------------------- ---------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the Financial ordinary shares of EUR1/15
instrument, type of instrument each
-------------------------------- ---------------------------------
Identification code FR0010397232
-------------------------------- ---------------------------------
b) Nature of the transaction Acquisition of Ordinary Shares
-------------------------------- ---------------------------------
c) Price(s) and volume(s) Price Volume
310 pence 9,493
-------
-------------------------------- ---------------------------------
d) Aggregated information:
-- Aggregated volume N/A Single transaction as
-- Price above Price Volume
310 pence 9,493
-------
-------------------------------- ---------------------------------
e) Date of the transaction
15 May 2020
-------------------------------- ---------------------------------
f) Place of the transaction AIM
-------------------------------- ---------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name
James Wakefield, Non-Executive
Director & Chairman of the
Board
-------------------------------- --------------------------------------
2. Reason for the Notification
------------------------------------------------------------------------
a) Position/status See 1(a) - classified as
PDMRs of the Company
-------------------------------- --------------------------------------
b) Initial notification/ Amendment Initial Notification
-------------------------------- --------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a) Name Novacyt S.A.
-------------------------------- --------------------------------------
b) LEI 213800BWAC2BF295EG28
-------------------------------- --------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------
a) Description of the Financial ordinary shares of EUR1/15
instrument, type of instrument each
-------------------------------- --------------------------------------
Identification code FR0010397232
-------------------------------- --------------------------------------
b) Nature of the transaction Acquisition of Ordinary Shares
-------------------------------- --------------------------------------
c) Price(s) and volume(s) Price Volume
a) 304.9 pence 20,000
-------
-------------------------------- --------------------------------------
d) Aggregated information:
-- Aggregated volume N/A single transaction as
-- Price above Price Volume
a) 304.9p 20,000
-------
-------------------------------- --------------------------------------
e) Date of the transaction
15 May 2020
-------------------------------- --------------------------------------
f) Place of the transaction AIM
-------------------------------- --------------------------------------
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
- End -
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
FTI Consulting (International)
Victoria Foster Mitchell / Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 47
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
For more information please refer to the website: www.novacyt.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHGPUAAAUPUUMR
(END) Dow Jones Newswires
May 18, 2020 04:00 ET (08:00 GMT)
1 Year Novacyt Chart |
1 Month Novacyt Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
